biostudies-literatureMaunsell ENCI NIH HHSCIHR1427-36https://www.ebi.ac.uk/biostudies/studies/S-EPMC4879707biostudies-literatureUnknown32(14)<h4>Purpose</h4>Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial, but effects on quality of life (QOL) were not fully described.<h4>Patients and methods</h4>Menopause-specific and health-related QOL were assessed by using the four Menopause-Specific Quality of Life Questionnaire (MENQOL) domains and the eight Medical Outcomes Study Short Form Health Survey (SF-36) scales at baseline, 6 months, and yearly thereafter. MENQOL questionnaire completion was high (88% to 98%) in both groups at each follow-up visit. Change scores for each MENQOL anJournal of clinical oncology : official journal of the American Society of Clinical OncologyQuality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.PMC4879707P30 CA015083Sarto GECheung AMWactawski-Wende JEllard SLHiltz ALickley LDube PAles-Martinez JEIngle JNCooke ALPujol PGelmon KAMaunsell EGoss PEPater JLTu DChlebowski RTSpadafora SPruthi SJohnston DRichardson HThayer DWFabian CJRuiz ABrundage MRowland KMHendrix SfalseQuality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer.<h4>Purpose</h4>Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Trials Group MAP.3 (Mammary Prevention 3) trial, but effects on quality of life (QOL) were not fully described.<h4>Patients and methods</h4>Menopause-specific and health-related QOL were assessed by using the four Menopause-Specific Quality of Life Questionnaire (MENQOL) domains and the eight Medical Outcomes Study Short Form Health Survey (SF-36) scales at baseline, 6 months, and yearly thereafter. MENQOL questionnaire completion was high (88% to 98%) in both groups at each follow-up visit. Change scores for each MENQOL an2014-01-01T00:00:00Z2014 May2026-05-30T08:49:03.724Z2019-03-26T23:50:04ZS-EPMC48797072471155210.1200/JCO.2013.51.248310.1200/jco.2013.51.2483